The Policy Planning Blueprint
Is your policy planning stuck in a short-term tactical cycle while your pipeline spans a decade? When planning starts late and in isolation, organisations miss critical opportunities to build stakeholder awareness, bridge gaps in the patient journey, and accelerate future uptake.
This is why I developed the Policy Planning Blueprint. It is designed to move teams from disjointed functional goals to a single, agreed-upon set of cross-functional priorities aligned around patient access and commercial success.
- 1. Early, Cross-Functional Alignment Fragmented priorities are the silent killer of Market Access. The Blueprint rallies the cross-functional team around joint goals early, ensuring every function speaks with one voice.
- 2. Clear Accountability for Execution A strategy is only as powerful as the team’s willingness and ability to execute it. The framework ensures clear accountabilities, removing the real-world friction of cross-functional decision-making.
- 3. Well-Defined KPIs We establish objective metrics to track progress, replacing theoretical planning with proven best practices and measurable success.
The Blueprint in Action: For a global biopharma leader, this methodology successfully orchestrated the shift to a 5-year strategic horizon. We closed gaps in the patient journey through disease awareness and expanded diagnosis. And we developed a comprehensive value concept to guiding evidence generation and engagement with policy makers, HTA agencies and payers globally.
Co-Creation over Consulting Reports
Most consulting reports gather dust because they are "delivered" to a team rather than co-created with them. The Policy Planning Blueprint is designed to solve this by prioritising full internal ownership from day one.
Operating on a lean, responsive model, we ensure direct collaboration without the overhead of large agencies. Through rapid piloting,"train-the-trainer" workshops and capability-building, your organisation doesn’t just receive a plan—it gains the expertise to navigate the policy environment long after the project is complete. It’s about building a sustainable internal engine for market success.
Explore how the Blueprint can drive patient access and commercial success.
Macro-Policy Expertise
Effective policy strategy requires a deep understanding of the regulatory forces reshaping the global landscape. Explore my latest systemic analyses below.
The end of the global pharma model.
The pharmaceutical industry’s unitary global business model is facing unprecedented pressure from the implementation of Most Favored Nation reference pricing in the U.S. Simultaneously, the Inflation Reduction Act’s "Pill Penalty" and the "Orphan Loophole" introduced with the One Big Beautiful Bill Act are triggering a radical review of R&D pipelines.
While the industry is still exploring tactical defenses, this analysis argues that these pressures ultimately lead to one unavoidable conclusion: geographic spin-offs. Just as the industry previously separated innovative pharma from off-patent portfolios and consumer health, the next wave of value creation will require separating high-value U.S. assets from price-controlled international portfolios.
The unintended deadlock.
Having previously reviewed the impact of U.S. and EU policy on the pharmaceutical industry, this analysis assesses the human cost of the unintended regulatory deadlock.
U.S. MFN pricing is forcing strategic launch delays and the "pill penalty" is devaluing shelf-stable oral treatments that are the backbone of global health. As pipelines pivots toward complex biologics and genetic stratification, a new "precision barrier" is rising for any system lacking the necessary diagnostic infrastructure.
As traditional biopharma becomes more U.S.-centric, new innovation hubs in China and India will likely arise to provide a competitive counterweight for those stranded by Western regulatory blind spots.
The Sovereign Health Fund.
Most-favored-nation (MFN) deals signed by major pharmaceutical companies with the U.S. government explicitly foresee the repatriation of increased foreign revenues “to lower drug prices for American patients and taxpayers”. For international health systems, this means higher net prices would effectively subsidize U.S. healthcare and private investors.
The Sovereign Health Fund is the strategic architecture designed to stop this wealth transfer. It guarantees MFN-aligned prices, secures patient access to innovative treatments, but redistributes revenues to healthcare systems of participating countries.
